Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

Handok

Status and phase: Completed; Phase 1

Conditions: Healthy Volunteers

Treatments: Drug: Teneligliptin and Empagliflozin; Drug: HD-P023

Study type: Interventional

Funder types: Industry

Identifiers

NCT07102719

HD-MP-109

Details and patient eligibility

About

The purpose of this study is to compare the pharmacokinetics and safety of HDP023 and coadministration of Teneligliptin and Empagliflozin in healthy adult volunteers

Enrollment: 40 patients

Sex: All

Ages: 19+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients who are 19 years or older on screening
• Signed informed consent
• Healthy Volunteer
• Other inclusion applies

Exclusion criteria

• Clinically relevant/significant findings as evaluated by the investigator
• Other exclusion applied

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

40 participants in 2 patient groups

HD-P023

Experimental group

Description:

One tablet of HD-P023 by oral

Treatment:

Drug: HD-P023

Co-administration of Teneligliptin and Empagliflozin High

Active Comparator group

Description:

One tablet each of Teneligliptin and Empagliflozin High by oral

Treatment:

Drug: Teneligliptin and Empagliflozin